Edition:
United Kingdom

People: Invuity Inc (IVTY.OQ)

IVTY.OQ on NASDAQ Stock Exchange Global Market

7.39USD
22 Oct 2018
Change (% chg)

$-0.01 (-0.14%)
Prev Close
$7.40
Open
$7.40
Day's High
$7.40
Day's Low
$7.39
Volume
25,511
Avg. Vol
54,169
52-wk High
$9.55
52-wk Low
$2.35

Zadno, Reza 

Dr. Reza Zadno is an Independent Director of the Company. since January 2013. Dr. Zadno has served as a member of our board of directors since January 2013. From September 2016, Dr. Zadno served as the chief executive officer at Avedro Inc., an InterWest Partners portfolio company and ophthalmic pharmaceutical and medical device company. From July 2016 to August 2016, Dr. Zadno served as interim chief executive officer at Avedro. Since January 2015, Dr. Zadno has served as an Innovation Advisor to Novartis Venture Fund and has served as an Executive in Residence at InterWest Partners, a venture capital firm, where he served as a Venture Partner from January 2012 to December 2014. From January 2011 to January 2012, Dr. Zadno served as a Venture Partner at New Leaf Venture Partners, a venture capital firm. From March 2001 to September 2009, Dr. Zadno was founder, President, and Chief Executive Officer of Visiogen, a medical device company, which was acquired by Abbott-Medical Optics, a medical supply company, in 2009, at which time Dr. Zadno served as its General Manager until January 2011. From August 2000 to March 2001, Dr. Zadno worked as Entrepreneur in Residence at Three Arch Partners, a healthcare investment firm. Dr. Zadno currently serves on the board of directors of Autonomic Technologies, Carbylan Therapeutics and Gobiquity. Dr. Zadno received a Ph.D. (Docteur-Ingenieur) in Mechanical Properties of Materials from Ecole des Mines de Paris. We believe Dr. Zadno is qualified to serve on our board because of his medical background, venture capital experience and his leadership and management experience.

Basic Compensation

Total Annual Compensation, USD 126,336
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 62,438
Fiscal Year Total, USD 188,774

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --